Glioblastoma (GBM), one of the most aggressive types of brain cancer, is one of the greatest challenges for medicine, both ...

Under the terms of the settlement, Allarity has consented, without admitting or denying the SEC's findings, to the entry of ...

Coventry and Warwickshire’s leading medical negligence practitioners, is offering its professional support to patients ...

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...

Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatmentFully funded by the U.S. Veterans’ Administration Special Emphasis Pane ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.

Richard Walker – and another 13 patients – say they were treated with temozolomide for longer than the recommended six months - in Mr Walker's case more than a year longer A brain cancer ...